ONCR · Oncorus, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.63M | - | $14.09M | $12.48M | $12.47M | - | $11.30M | $10.66M | $5.89M | - |
| SG&A | $4.50M | - | $5.21M | $6.16M | $5.35M | - | $5.44M | $2.01M | $2.05M | - |
| Total Operating Expenses | $15.13M | - | $19.30M | $18.64M | $17.82M | - | $16.74M | $8.75M | $7.94M | - |
| D&A | $1.10M | - | - | - | $583.0K | - | - | - | $309.0K | - |
| Operating Income | ($29.70M) | - | ($19.30M) | ($18.64M) | ($17.82M) | - | ($16.74M) | ($8.75M) | ($7.94M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($30.90M) | - | ($19.62M) | ($19.09M) | ($17.78M) | - | ($16.73M) | ($9.37M) | ($7.83M) | - |
| EPS - Basic | ($0.69) | - | ($0.76) | ($0.60) | - | - | - | - | - | - |
| EPS - Diluted | ($1.18) | - | ($0.76) | ($0.60) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.22M | $25.71M | $41.57M | $84.80M | $75.51M | $100.75M | $145.60M | $28.92M | $172.62M | $130.31M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.76M | $5.69M | $1.98M | $7.16M | $3.58M | $13.01M | $1.43M | $1.96M | $2.52M | $1.25M |
| Current Assets | $46.67M | $64.62M | $83.48M | $102.76M | $102.61M | $129.11M | $147.71M | $162.69M | $175.53M | $133.39M |
| Total Assets | $109.75M | $145.59M | $164.37M | $182.54M | $176.57M | $201.59M | $202.73M | $215.61M | $225.11M | $182.26M |
| Current Liabilities | $31.11M | $37.21M | $16.81M | $16.02M | $12.14M | $20.97M | $12.34M | $10.74M | $6.77M | $5.98M |
| Long-term Debt | $20.00M | $20.00M | $19.26M | $0 | - | $0 | - | - | - | - |
| Total Liabilities | $78.63M | $85.06M | $84.37M | $84.53M | $62.31M | $71.56M | $54.88M | $52.98M | $48.85M | $47.60M |
| Stockholders' Equity | $31.12M | $60.52M | $80.00M | $98.01M | $114.26M | $130.02M | $147.84M | $162.63M | ($84.54M) | $134.66M |
| Retained Earnings | ($302.91M) | ($272.01M) | ($251.08M) | ($231.46M) | ($212.37M) | ($194.59M) | ($174.74M) | ($158.02M) | ($142.49M) | ($129.82M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($17.45M) | - | - | - | ($23.44M) | - | - | - | ($8.69M) | - |
| Investing Cash Flow | $12.96M | - | - | - | ($1.87M) | - | - | - | ($233.0K) | - |
| Financing Cash Flow | $0 | - | - | - | $62.0K | - | - | - | $5.0K | - |
| CapEx | $73.0K | - | - | - | $1.87M | - | - | - | $233.0K | - |
| Free Cash Flow | ($17.52M) | - | - | - | ($25.30M) | - | - | - | ($8.92M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.57 | - | - | - | 1.42 | - | - | - | 1.14 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -28.2% | - | -11.9% | -10.5% | -10.1% | - | -8.3% | -4.3% | -3.5% | - |
| Return on equity | -99.3% | - | -24.5% | -19.5% | -15.6% | - | -11.3% | -5.8% | 9.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.50 | 1.74 | 4.97 | 6.42 | 8.45 | 6.16 | 11.97 | 15.14 | 25.93 | 22.29 |
| Quick ratio | 1.50 | 1.74 | 4.97 | 6.42 | 8.45 | 6.16 | 11.97 | 15.14 | 25.93 | 22.29 |
| Cash ratio | 0.68 | 0.69 | 2.47 | 5.29 | 6.22 | 4.80 | 11.80 | 2.69 | 25.50 | 21.78 |
| Leverage | ||||||||||
| Debt / Equity | 0.64 | 0.33 | 0.24 | 0.00 | - | 0.00 | - | - | - | - |
| Debt / Assets | 0.18 | 0.14 | 0.12 | 0.00 | - | 0.00 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.53 | 2.41 | 2.05 | 1.86 | 1.55 | 1.55 | 1.37 | 1.33 | -2.66 | 1.35 |
| Liabilities / Assets | 0.72 | 0.58 | 0.51 | 0.46 | 0.35 | 0.36 | 0.27 | 0.25 | 0.22 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -66.7% | - | -15.3% | -113.1% | -124.3% | - | -88.1% | - | - | - |
| Net income growth (YoY) | -73.8% | - | -17.3% | -103.7% | -127.2% | - | 14.4% | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 30.8% | - | - | - | -183.6% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -72.8% | -53.5% | -45.9% | -39.7% | - | -3.4% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Oncorus against the 5 most active filers in the same SIC group.